Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Zi-Yi Xu & Jun-Ling Li. (2019) Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. OncoTargets and Therapy 12, pages 5467-5484.
Read now
Read now
Yongqiang Chen, Elizabeth S. Henson, Wenyan Xiao, Daniel Huang, Eileen M. McMillan-Ward, Sara J. Israels & Spencer B. Gibson. (2016) Tyrosine kinase receptor EGFR regulates the switch in cancer cells between cell survival and cell death induced by autophagy in hypoxia. Autophagy 12:6, pages 1029-1046.
Read now
Read now
Yuan-Yuan Chen, Lin-Wei Wang, Shu-Yi Wang, Bi-Bo Wu, Zhen-Meng Wang, Fang-Fang Chen & Bin Xiong. (2015) Meta-analysis of postoperative adjuvant chemotherapy without radiotherapy in early stage non-small cell lung cancer. OncoTargets and Therapy 8, pages 2033-2043.
Read now
Read now
Articles from other publishers (49)
Giulia Pretelli, Calogera Claudia Spagnolo, Giuliana Ciappina, Mariacarmela Santarpia & Giulia Pasello. (2023) Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need. International Journal of Molecular Sciences 24:10, pages 8878.
Crossref
Crossref
Xiaodi Lv, Zixian Mao, Xianjun Sun & Baojun Liu. (2023) Intratumoral Heterogeneity in Lung Cancer. Cancers 15:10, pages 2709.
Crossref
Crossref
Kyunghoon Lee, Sangeun Lim, Yun‐Gyoo Lee, Haejeung Kim, Seungjun Lee, Hui‐Jin Yu, Hyosoon Park, Min‐Jung Kwon & Hee‐Yeon Woo. (2022) Evaluation of molecular methods for plasma detection of EGFR mutations in non‐small cell lung cancer. Asia-Pacific Journal of Clinical Oncology 18:6, pages 595-604.
Crossref
Crossref
Yuki Katayama, Tadaaki Yamada, Shinsaku Tokuda, Naoko Okura, Naoya Nishioka, Kenji Morimoto, Keiko Tanimura, Yoshie Morimoto, Masahiro Iwasaku, Mano Horinaka, Toshiyuki Sakai, Kenji Kita, Seiji Yano & Koichi Takayama. (2022)
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring
EGFR
‐T790M mutation in non‐small cell lung cancer cells
. Cancer Medicine 11:4, pages 944-955.
Crossref
Crossref
Daniel J. Craig, Morgan M. Bailey, Olivia B. Noe, Kada K. Williams, Laura Stanbery, Danae M. Hamouda & John J. Nemunaitis. (2022) Subclonal landscape of cancer drives resistance to immune therapy. Cancer Treatment and Research Communications 30, pages 100507.
Crossref
Crossref
B.W. Carter, M. Altan, G.S. Shroff, M.T. Truong & I. Vlahos. (2022) Post-chemotherapy and targeted therapy imaging of the chest in lung cancer. Clinical Radiology 77:1, pages e1-e10.
Crossref
Crossref
Takshveer Singh, Mortaza Fatehi Hassanabad & Ali Fatehi Hassanabad. (2021) Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1876:2, pages 188636.
Crossref
Crossref
Chun‐Hau Dai, Li‐Rong Zhu, Yi Wang, Xing‐Ping Tang, Yong‐Jie Du, Yong‐Chang Chen & Jian Li. (2020) Celastrol acts synergistically with afatinib to suppress non‐small cell lung cancer cell proliferation by inducing paraptosis. Journal of Cellular Physiology 236:6, pages 4538-4554.
Crossref
Crossref
Fariz Nurwidya, Fumiyuki Takahashi, Wira Winardi, Ken Tajima, Yoichiro Mitsuishi, Akiko Murakami, Isao Kobayashi, Takeshi Nara, Muneaki Hashimoto, Motoyasu Kato, Moulid Hidayat, Kentaro Suina, Daisuke Hayakawa, Tetsuhiko Asao, Ryo Ko, Takehito Shukuya, Toshifumi Yae, Naoko Shimada, Yasuko Yoshioka, Shinichi Sasaki & Kazuhisa Takahashi. (2021)
Zinc‐finger E‐box‐binding homeobox 1
(ZEB1)
plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
. Thoracic Cancer 12:10, pages 1536-1548.
Crossref
Crossref
Fangqiu Fu, Zhexu Wen, Zhendong Gao, Yue Zhao, Yuan Li, Yang Zhang & Haiquan Chen. (2021) Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma. Frontiers in Oncology 11.
Crossref
Crossref
Paul Stockhammer, Cassandra Su Lyn Ho, Luca Hegedus, Gabor Lotz, Eszter Molnár, Agnes Bankfalvi, Thomas Herold, Stavros Kalbourtzis, Till Ploenes, Wilfried E.E. Eberhardt, Martin Schuler, Clemens Aigner, Alexander Schramm & Balazs Hegedus. (2020) HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. Lung Cancer 144, pages 20-29.
Crossref
Crossref
Frederik van Delft, Hendrik Koffijberg, Valesca Retèl, Michel van den Heuvel & Maarten IJzerman. (2020) The Validity and Predictive Value of Blood-Based Biomarkers in Prediction of Response in the Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review. Cancers 12:5, pages 1120.
Crossref
Crossref
Wen-juan Liu, Yue Du, Ru Wen, Ming Yang & Jian Xu. (2020) Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacology & Therapeutics 206, pages 107438.
Crossref
Crossref
Jie Zhang, Yifan Song, Yuan Liang, Haoyang Zou, Peng Zuo, Mi Yan, Siyuan Jing, Tiezhu Li, Yongjun Wang, Da Li, Tiehua Zhang & Zhengyi Wei. (2019) Cucurbitacin IIa interferes with EGFR-MAPK signaling pathway leads to proliferation inhibition in A549 cells. Food and Chemical Toxicology 132, pages 110654.
Crossref
Crossref
Hao Bai, Jinjing Xia, Xiaokai Zhao, Ziying Gong, Daoyun Zhang & liwen Xiong. (2019)
Detection of
EGFR
mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer
. Journal of Clinical Pathology 72:5, pages 379-385.
Crossref
Crossref
Md. Maqusood Alam, Ahmed H.E. Hassan, Kun Won Lee, Min Chang Cho, Ji Seul Yang, Jiho Song, Kyung Hoon Min, Jongki Hong, Dong-Hyun Kim & Yong Sup Lee. (2019) Design, synthesis and cytotoxicity of chimeric erlotinib-alkylphospholipid hybrids. Bioorganic Chemistry 84, pages 51-62.
Crossref
Crossref
Yangyang Cai, Xu Wang, Ye Guo, Chao Sun, Yinghui Xu, Shi Qiu & Kewei Ma. (2019) Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib. Medicine 98:1, pages e13890.
Crossref
Crossref
Pei-Ying Lin, Yu-Jung Chang, Yu-Chen Chen, Chin-Hung Lin, Pinar Erkekoglu, Ming-Wei Chao & Chia-Yi Tseng. (2018) Anti-cancer effects of 3,5-dimethylaminophenol in A549 lung cancer cells. PLOS ONE 13:10, pages e0205249.
Crossref
Crossref
Takafumi Hashimoto, Atsushi Osoegawa, Yohei Takumi, Miyuki Abe, Ryoji Kobayashi, Michiyo Miyawaki, Hideya Takeuchi, Tatsuro Okamoto & Kenji Sugio. (2018) Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining. Lung Cancer 124, pages 241-247.
Crossref
Crossref
Lucheng Zhu, Shirong Zhang, Yanping Xun, Yanping Jiang, Bing Xia, Xueqin Chen, Limin Wang, Hong Jiang & Shenglin Ma. (2017) Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment. Pathology & Oncology Research 24:4, pages 843-851.
Crossref
Crossref
Claudio Sini, Alessandro Tuzi, Giovanni Rossi, Alessandro Russo & Aldo Pezzuto. (2018) Acquired resistance in oncogene-addicted non-small-cell lung cancer. Future Oncology 14:13s, pages 29-40.
Crossref
Crossref
Marzia Del Re, Elena Arrigoni, Giuliana Restante, Antonio Passaro, Eleonora Rofi, Stefania Crucitta, Filippo De Marinis, Antonello Di Paolo & Romano Danesi. (2018) Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. Stem Cells 36:5, pages 633-640.
Crossref
Crossref
Zhou Qiang, Li Jun-jie, Wang Hai, Li Hong, Lei Bing-xi, Chen Lei, Xiang Wei, Liu Ya-wei, Annie Huang, Qi Song-tao & Lu Yun-tao. (2018) TPD52L2 impacts proliferation, invasiveness and apoptosis of glioblastoma cells via modulation of wnt/β-catenin/snail signaling. Carcinogenesis 39:2, pages 214-224.
Crossref
Crossref
Yanlei Li, Baocun Sun, Xiulan Zhao, Xudong Wang, Danfang Zhang, Qiang Gu & Tieju Liu. (2017) MMP-2 and MMP-13 affect vasculogenic mimicry formation in large cell lung cancer. Journal of Cellular and Molecular Medicine 21:12, pages 3741-3751.
Crossref
Crossref
Ahmed Elkamhawy, Sora Paik, Ahmed H.E. Hassan, Yong Sup Lee & Eun Joo Roh. (2017) Hit discovery of 4-amino- N -(4-(3-(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide: A novel EGFR inhibitor from a designed small library. Bioorganic Chemistry 75, pages 393-405.
Crossref
Crossref
F. Rodriguez-Panadero. (2017) The case for performing pleural biopsies for the aetiological diagnosis of exudates. Yes. Revista Clínica Española (English Edition) 217:7, pages 420-422.
Crossref
Crossref
F. Rodriguez-Panadero. (2017) ¿Se debe realizar una biopsia pleural para el diagnóstico etiológico de los exudados? Sí. Revista Clínica Española 217:7, pages 420-422.
Crossref
Crossref
Ning An & Xue Yang. (2017) Identification of prognostic genes through expression differentiation during metastatic process in lung adenocarcinoma. Scientific Reports 7:1.
Crossref
Crossref
Yongjia Hao, Jiankun Lyu, Rong Qu, Deheng Sun, Zhenjiang Zhao, Zhuo Chen, Jian Ding, Hua Xie, Yufang Xu & Honglin Li. (2017) Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. Scientific Reports 7:1.
Crossref
Crossref
Sami Morin-Ben Abdallah & Vera Hirsh. (2017) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. Frontiers in Oncology 7.
Crossref
Crossref
M. K. Ibragimova, M. M. Tsyganov & N. V. Litviakov. (2017) Natural and chemotherapy-induced clonal evolution of tumors. Biochemistry (Moscow) 82:4, pages 413-425.
Crossref
Crossref
Mateusz Florczuk, Adam Szpechcinski & Joanna Chorostowska-Wynimko. (2017) miRNAs as Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer: Current Perspectives. Targeted Oncology 12:2, pages 179-200.
Crossref
Crossref
Juan Sebastian Yakisich, Neelam Azad, Vivek Kaushik, George A O’Doherty & Anand Krishnan V Iyer. (2017) Nigericin decreases the viability of multidrug-resistant cancer cells and lung tumorspheres and potentiates the effects of cardiac glycosides. Tumor Biology 39:3, pages 101042831769431.
Crossref
Crossref
Jonas Leichsenring, Anna-Lena Volckmar, Nikolaus Magios, Cristiano Manuel Morais de Oliveira, Roland Penzel, Regine Brandt, Martina Kirchner, Farastuk Bozorgmehr, Michael Thomas, Peter Schirmacher, Arne Warth, Volker Endris & Albrecht Stenzinger. (2017) Synonymous EGFR variant p.Q787Q is neither prognostic nor predictive in patients with lung adenocarcinoma. Genes, Chromosomes and Cancer 56:3, pages 214-220.
Crossref
Crossref
Walter Arancio, Beatrice Belmonte, Marta Castiglia, Arianna Di Napoli & Claudio Tripodo. 2017. Liquid Biopsy in Cancer Patients. Liquid Biopsy in Cancer Patients
41
49
.
Xin-Min Yu, Yi-Chen Wu, Xiang Liu, Xian-Cong Huang, Xiu-Xiu Hou, Jiu-Li Wang, Xiang-Liu Cheng, Wei-Min Mao & Zhi-Qiang Ling. (2016) Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma. International Journal of Molecular Sciences 17:11, pages 1845.
Crossref
Crossref
Harvey I. Pass, Carmencita Lavilla, Claudia Canino, Chandra Goparaju, Jordan Preiss, Samrah Noreen, Giovanni Blandino & Mario Cioce. (2016) Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin. Oncotarget 7:35, pages 56408-56421.
Crossref
Crossref
Jian-Shu Lou, Lu Yan, Cathy W. C. Bi, Gallant K. L. Chan, Qi-Yun Wu, Yun-Le Liu, Yun Huang, Ping Yao, Crystal Y. Q. Du, Tina T. X. Dong & Karl W. K. Tsim. (2016) Yu Ping Feng San reverses cisplatin-induced multi-drug resistance in lung cancer cells via regulating drug transporters and p62/TRAF6 signalling. Scientific Reports 6:1.
Crossref
Crossref
Chia-Yi Tseng, Chin-Hung Lin, Lung-Yuan Wu, Jhih-Syuan Wang, Meng-Chi Chung, Jing-Fen Chang & Ming-Wei Chao. (2016) Potential Combinational Anti-Cancer Therapy in Non-Small Cell Lung Cancer with Traditional Chinese Medicine Sun-Bai-Pi Extract and Cisplatin. PLOS ONE 11:5, pages e0155469.
Crossref
Crossref
Lin Feng, Run Tong, Xiaohong Liu, Kaitai Zhang, Guiqi Wang, Lei Zhang, Ning An & Shujun Cheng. (2016) A network-based method for identifying prognostic gene modules in lung squamous carcinoma. Oncotarget 7:14, pages 18006-18020.
Crossref
Crossref
JUAN SEBASTIAN YAKISICH, NEELAM AZAD, RAJKUMAR VENKATADRI, YOGESH KULKARNI, CLAYTON WRIGHT, VIVEK KAUSHIK, GEORGE A. O'DOHERTY & ANAND KRISHNAN V. IYER. (2016) Digitoxin and its synthetic analog MonoD have potent antiproliferative effects on lung cancer cells and potentiate the effects of hydroxyurea and paclitaxel. Oncology Reports 35:2, pages 878-886.
Crossref
Crossref
D. S. Mikhaylenko, G. D. Efremov, A. V. Sivkov & D. V. Zaletaev. (2016) Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer. Molecular Biology 50:1, pages 28-36.
Crossref
Crossref
Nicole Pfarr, Albrecht Stenzinger, Roland Penzel, Arne Warth, Hendrik Dienemann, Peter Schirmacher, Wilko Weichert & Volker Endris. (2016) High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer. Genes, Chromosomes and Cancer 55:1, pages 30-44.
Crossref
Crossref
Srivatsava Naidu & Michela Garofalo. (2015) microRNAs: An Emerging Paradigm in Lung Cancer Chemoresistance. Frontiers in Medicine 2.
Crossref
Crossref
Ning An, Xiaoyu Shi, Yueming Zhang, Ning Lv, Lin Feng, Xuebing Di, Naijun Han, Guiqi Wang, Shujun Cheng & Kaitai Zhang. (2015) Discovery of a Novel Immune Gene Signature with Profound Prognostic Value in Colorectal Cancer: A Model of Cooperativity Disorientation Created in the Process from Development to Cancer. PLOS ONE 10:9, pages e0137171.
Crossref
Crossref
Elisabete Fernandes, José Alexandre Ferreira, Peixoto Andreia, Lima Luís, Sérgio Barroso, Bruno Sarmento & Lúcio Lara Santos. (2015) New trends in guided nanotherapies for digestive cancers: A systematic review. Journal of Controlled Release 209, pages 288-307.
Crossref
Crossref
Vera Hirsh. (2015) Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib. BioDrugs 29:3, pages 167-183.
Crossref
Crossref
Ying‐Chao Yang & Xiao‐Ping Li. (2015) Clinical significance of intratumor heterogeneity for gynecological carcinoma. Chronic Diseases and Translational Medicine 1:1, pages 14-17.
Crossref
Crossref
Anxin Wang, Lisha Chen, Chunlin Li & Yimin Zhu. (2015) Heterogeneity in cancer stem cells. Cancer Letters 357:1, pages 63-68.
Crossref
Crossref